{
  "id": 12745604,
  "title": "Grail CFO Aaron Freidin sells $3.46m in company stock",
  "url": "https://urgent.news/2026/10/07/grail-cfo-aaron-freidin-sells-3-46m-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-07T23:46:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/grail-cfo-aaron-freidin-sells-346m-in-company-stock-93CH-4937726"
  },
  "original_language": "en",
  "account": "CFO Aaron Freidin of GRAIL, Inc. divested 23,619 shares of the company's stock on October 5, 2026, generating around $3.46 million in proceeds. The sales occurred through automatic transactions executed by a broker to satisfy withholding taxes upon award vesting and share delivery. Following the sales, Mr. Freidin retained ownership of 225,364 GRAIL shares. At the time of the sales, GRAIL's stock was trading at $132.90, a decline from the $146.39 per share at which Freidin sold his shares. Despite the recent price drop, the stock has shown impressive growth, with a 170% return over the past six months and a 112% return over the past year, according to InvestingPro data. GRAIL's beta of 2.84 suggests increased volatility compared to the broader market. Analysts indicate that GRAIL is currently overvalued, being listed among stocks on the most overvalued list in InvestingPro analysis. The company has been making significant strides with its Galleri multi-cancer early detection test, which recently received positive votes from the FDA advisory committee on both safety and effectiveness. However, concerns remain regarding reimbursement and adoption. Multiple financial institutions have adjusted their price targets for GRAIL shares, with Canaccord Genuity raising its target to $150 and maintaining a Buy rating, and Mizuho increasing its target to $100 with a Neutral rating. Despite these developments, RBC Capital remains cautious, initiating coverage with a Sector Perform rating and a price target of $84, citing uncertainties related to reimbursement and adoption.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Grail chief growth officer Andrew Partridge sells $1.15m in stock",
        "url": "https://urgent.news/2026/10/07/grail-chief-growth-officer-andrew-partridge-sells-1-15m-in-stock",
        "published": "2026-10-07T23:46:16.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}